Q-omics provides the consensus-scored TMBIM6 profile across patient tissues and cancer cell-line models. TMBIM6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMBIM6 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, TMBIM6 RNA expression shows 19,219 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, BRCA, and ACC as cancer lineages where TMBIM6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMBIM6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMBIM6 survival associations across molecular data types. TMBIM6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMBIM6 RNA expression–survival associations across cancer types. High TMBIM6 expression shows unfavorable associations in HNSC, UVM, CESC and ACC, but favorable associations in KIRC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TMBIM6 RNA expression.
This table summarizes TMBIM6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in BRCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMBIM6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMBIM6 shows lower tumor expression in LUSC, THCA and LUAD and higher tumor expression in BRCA, BLCA and HNSC. The BRCA box plot shows higher TMBIM6 RNA expression in tumor versus normal tissue (log2 FC = +0.640, t-test p < 0.001).
This table shows molecular features associated with TMBIM6 in patient tissues and cancer cell lines. In patient samples, TMBIM6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMBIM6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
